# Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update

*PRI Rank #3 · Topics and Trends in Most Cited Hepatocellular Carcinoma Treatment and Prognosis Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/hepatocellular-carcinoma-treatment-and-prognosis/2026/rank-3*

| Field | Value |
| --- | --- |
| Rank | #3 |
| 18m citations | 144 |
| Journal | Journal of Clinical Oncology |
| Year | 2024 |
| DOI | 10.1200/jco.23.02745 |
| Corresponding authors | John D Gordan |
| Institution | University of California, San Francisco, United States |

**Ranking page:** [Topics and Trends in Most Cited Hepatocellular Carcinoma Treatment and Prognosis Papers, Class of 2026](https://pri.pepkio.com/top-papers/hepatocellular-carcinoma-treatment-and-prognosis/2026)

**Paper link:** [10.1200/jco.23.02745](https://doi.org/10.1200/jco.23.02745)

## Topics

Hepatocellular carcinoma · Advanced hepatocellular carcinoma · Systemic therapy · Atezolizumab plus bevacizumab · Durvalumab plus tremelimumab · sorafenib · lenvatinib · nivolumab + ipilimumab · pembrolizumab · nivolumab · durvalumab · cabozantinib · regorafenib · ramucirumab · Tyrosine kinase inhibitor · Immune checkpoint inhibitor therapy · alpha-fetoprotein · Child-Pugh class · Performance status · First-line treatment · Second-line therapy · third-line therapy · Randomized controlled trial · ASCO guideline · Clinical practice guidelines · PD-1/PD-L1 inhibitor · CTLA-4 inhibition · VEGF inhibition · liver disease · systematic review

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Hepatocellular Carcinoma Treatment and Prognosis Papers, Class of 2026. https://pri.pepkio.com/top-papers/hepatocellular-carcinoma-treatment-and-prognosis/2026. Accessed 2026-07-14.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```